Jazz Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. 

CEO
Renée D. Galá
CEORenée D. Galá
Employees
2,890
Employees2,890
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2005
Founded2005
Employees
2,890
Employees2,890

JAZZ Key Statistics

Market cap
16.58B
Market cap16.58B
Price-Earnings ratio
-13,742.39
Price-Earnings ratio-13,742.39
Dividend yield
Dividend yield
Average volume
671.49K
Average volume671.49K
High today
$259.06
High today$259.06
Low today
$250.00
Low today$250.00
Open price
$258.09
Open price$258.09
Volume
572.98K
Volume572.98K
52 Week high
$261.30
52 Week high$261.30
52 Week low
$105.00
52 Week low$105.00

Stock Snapshot

As of today, Jazz Pharmaceuticals(JAZZ) shares are valued at $250.00. The company's market cap stands at 16.58B, with a P/E ratio of -13742.39.

During the trading session on 2026-08-02, Jazz Pharmaceuticals(JAZZ) shares reached a daily high of $259.06 and a low of $250.00. At a current price of $250.00, the stock is 0.0% higher than the low and still -3.5% under the high.

Trading activity shows a volume of 572.98K, compared to an average daily volume of 671.49K.

The stock's 52-week range extends from a low of $105.00 to a high of $261.30.

The stock's 52-week range extends from a low of $105.00 to a high of $261.30.

JAZZ News

TipRanks 3d
Jazz Pharmaceuticals Advances JZP3507 Trial in Aggressive Brain Tumors

Jazz Pharmaceuticals (JAZZ) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

Simply Wall St 5d
Should Anticipated Earnings Beat and Employer Award Recognition Require Action From Jazz Pharmaceuticals Investors?

Jazz Pharmaceuticals recently reported that analysts had expected a very large year-over-year earnings increase to US$6.04 per share on revenues of about US$1.1...

Should Anticipated Earnings Beat and Employer Award Recognition Require Action From Jazz Pharmaceuticals Investors?
TipRanks 6d
Jazz Pharmaceuticals Targets Adult LGS Growth With New Cannabidiol Dosing Study

Jazz Pharmaceuticals (JAZZ) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
4.5%
Sell
9.1%

People also own

Based on the portfolios of people who own JAZZ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.